ANKRD44

Across TCGA pan-cancer cohorts, ANKRD44 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ANKRD44 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ANKRD44 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD44 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, OV, and ESCA are the cancer types where ANKRD44 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.055	0.702	<.001	30	view →
OV	DFS	Median	All	0.267	0.542	.036	18	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	18	view →
UCEC	DFS	Median	All	0.949	0.618	.007	10	view →
SARC	OS	Median	All	0.210	0.745	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.132	0.557	.002	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LGG	OS	Median	All	0.607	0.889	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ANKRD44–SCLC (OS)

Open the SCLC breakdown →